Ephedrae herba, a major component of maoto, inhibits the HGF-induced motility of human breast cancer MDA-MB-231 cells through suppression of c-met tyrosine phosphorylation and c-Met expression

Journal of Traditional Medicines

Volumn 28, Issue 3, 2011, Pages 128-138

  Hyuga, Sumiko ^a   Hanawa, Toshihiko ^a,b   Shiraishi, Masumi ^b   Hyuga, Masashi ^c   Goda, Yukihiro ^c  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

c Met; Ephedrae herba; HGF; maoto; MDA MB 231; motility

Indexed keywords

EID: 85024467788     PISSN: 18801447     EISSN: 18813747     Source Type: Journal    
DOI: 10.11339/jtm.28.128     Document Type: Article

References (33)

1. Aburada, M., Takeda, S., Ito, E., Nakamura, M. and Hosoya, E.: Protective effects of juzentaihoto, dried decoctum of 10 Chinese herbs mixture, upon the adverse effects of mitomycin C in mice. J. Pharmacobiodyn., 6, 1000-1004, 1983.
2. Ohnishi, Y., Yasumizu, R., Fan, H. X., Liu, J., Takao-Liu, F., Komatsu, Y., Hosoya, E., Good, R. A. and Ikehara, S.: Effects of juzen-taiho-toh (TJ-48), a traditional Oriental medicine, on hematopoietic recovery from radiation injury in mice. Exp. Hematol., 18, 18-22, 1990.
3. Sugiyama, K., Ueda, H. and Ichio, Y.: Protective effect of juzen-taiho-to against carboplatin-induced toxic side effects in mice. Biol. Pharm. Bull., 18, 544-548, 1995.
4. Sugiyama, K., Ueda, H., Ichio, Y. and Yokota, M.: Improvement of cisplatin toxicity and lethality by juzen-taiho-to in mice. Biol. Pharm. Bull., 18, 53-58, 1995.
5. Takegawa, Y.: Combined Kampo with radiation therapy prolongs survial in patients with cervical cancer. J. Trad. Med., 17, 108-114, 2000.
6. Ohnishi, Y., Fujii, H., Kimura, F., Mishima, T., Murata, J., Tazawa, K., Fujimaki, M., Okada, F., Hosokawa, M. and Saiki, I.: Inhibitory effect of a traditional Chinese medicine, Juzen-taiho-to, on progressive growth of weakly malignant clone cells derived from murine fibrosarcoma. Jpn. J. Cancer Res., 87, 1039-1044, 1996.
7. Ohnishi, Y., Fujii, H., Hayakawa, Y., Sakukawa, R., Yamaura, T., Sakamoto, T., Tsukada, K., Fujimaki, M., Nunome, S., Komatsu, Y. and Saiki, I.: Oral administration of a Kampo (Japanese herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells. Jpn. J. Cancer Res., 89, 206-213, 1998.
8. Ohno, T., Inoue, M. and Ogihara, Y.: Suppressive effect of Shichimotsu-koka-to (Kampo medicine) on pulmonary metastasis of B16 melanoma cells. Biol. Pharm. Bull., 25, 880-884, 2002.
9. Hyuga, S., Hyuga, M., Yamagata, S., Yamagata, T. and Hanawa, T.: Mao-to, a Kampo medicine, inhibits migration of highly metastatic osteosarcoma cells. J. Trad. Med., 21, 174-181, 2004.
10. Ito, H., Hyuga, S., Hyuga, M., Watanabe, K., Oikawa, T. and Hanawa, T.: Maoto, a Kampo medicine, suppresses human serum-induced motility of human breast cancer cells. J. Trad. Med., 24, 168-172, 2007.
11. Ito, H., Hyuga, S., Hyuga, M., Watanabe, K., Tsuda, T., Oikawa, T. and Hanawa, T.: Suppression of motility of human breast cancer cells by human serum after intake of maoto. J. Trad. Med., 26, 51-60, 2009.
12. Hyuga, S., Hyuga, M., Nakanishi, H., Ito, H., Watanabe, K., Oikawa, T. and Hanawa, T.: Maoto, Kampo medicine, suppresses the metastatic potential of highly metastatic osteosarcoma cells. J. Trad. Med., 24, 51-58, 2007.
13. Borgiel-Marek, H., Kajdaniuk, D., Niedzielska, I., Kos-Kudla, B., Tarabura-Dragon, J. and Marek, B.: Serum concentration of hepatocyte growth factor (HGF) in oral squamous cell carcinoma before and after surgery. Preliminary report. Endokrynol. Pol., 59, 467-470, 2008.
14. Junbo, H., Li, Q., Zaide, W. and Yunde, H.: Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis. In Vivo, 13, 177-180, 1999.
15. Weidner, K. M., Arakaki, N., Hartmann, G., Vandekerckhove, J., Weingart, S., Rieder, H., Fonatsch, C., Tsubouchi, H., Hishida, T., Daikuhara, Y. and et al.: Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. USA, 88, 7001-7005, 1991.
16. Eiichi, G.: Function and regulation of production of hepatocyte growth factor (HGF). Folia Pharmacologica Japonica, 119, 287-294, 2002.
17. Eder, J. P., Vande Woude, G. F., Boerner, S. A. and LoRusso, P. M.: Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res., 15, 2207-2214, 2009.
18. Takeuchi, H., Bilchik, A., Saha, S., Turner, R., Wiese, D., Tanaka, M., Kuo, C., Wang, H. J. and Hoon, D. S.: c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res., 9, 1480-1488, 2003.
19. Chin, Y. R. and Toker, A.: The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol. Cell, 38, 333-344, 2010.
20. Chin, Y. R. and Toker, A.: Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal., 21, 470-476, 2009.
21. Lee, W. J., Chen, W. K., Wang, C. J., Lin, W. L. and Tseng, T. H.: Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol. Appl. Pharmacol., 226, 178-191, 2008.
22. Que, W. and Chen, J.: Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol. Med. Report, 4, 343-349, 2011.
23. Liu, Y.: The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene, 215, 159-169, 1998.
24. Colon, J., Basha, M. R., Madero-Visbal, R., Konduri, S., Baker, C. H., Herrera, L. J., Safe, S., Sheikh-Hamad, D., Abudayyeh, A., Alvarado, B. and Abdelrahim, M.: Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest. New Drugs, 29, 41-51, 2009.
25. Kitani, Y., Zhu, S., Omote, T., Tanaka, K., Batkhuu, J., Sanchir, C., Fushimi, H., Mikage, M. and Komatsu, K.: Molecular analysis and chemical evaluation of ephedra plants in Mongolia. Biol. Pharm. Bull., 32, 1235-1243, 2009.
26. Comoglio, P. M., Giordano, S. and Trusolino, L.: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov., 7, 504-516, 2008.
27. Kundsen, B. S. and Woude, G. V.: Showering c-Met-dependent cancers with drugs. Current Opinion in Genetics & Development, 18, 87-96, 2008.
28. Schoffski, P., Garcia, J. A., Stadler, W. M., Gil, T., Jonasch, E., Tagawa, S. T., Smitt, M., Yang, X., Oliner, K. S., Anderson, A., Zhu, M. and Kabbinavar, F.: A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU. Int., 108, 679-686, 2010.
29. Yap, T. A., Olmos, D., Brunetto, A. T., Tunariu, N., Barriuso, J., Riisnaes, R., Pope, L., Clark, J., Futreal, A., Germuska, M., Collins, D., deSouza, N. M., Leach, M. O., Savage, R. E., Waghorne, C., Chai, F., Garmey, E., Schwartz, B., Kaye, de Bono, S. B. and de Bono, J. S.: Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol., 29, 1271-1279, 2011.
30. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C. and Janne, P. A.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-1043, 2007.
31. Tang, Z., Du, R., Jiang, S., Wu, C., Barkauskas, D. S., Richey, J., Molter, J., Lam, M., Flask, C., Gerson, S., Dowlati, A., Liu, L., Lee, Z., Halmos, B., Wang, Y., Kern, J. A. and Ma, P. C.: Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br. J. Cancer, 99, 911-922, 2008.
32. Towner, R. A., Smith, N., Doblas, S., Tesiram, Y., Garteiser, P., Saunders, D., Cranford, R., Silasi-Mansat, R., Herlea, O., Ivanciu, L., Wu, D. and Lupu, F.: In vivo detection of c-Met expression in a rat C6 glioma model. J. Cell Mol. Med., 12, 174-186, 2008.
33. Agarwal, S., Zerillo, C., Kolmakova, J., Christensen, J. G., Harris, L. N., Rimm, D. L., Digiovanna, M. P. and Stern, D. F.: Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br. J. Cancer, 100, 941-949, 2009.